BioAge Labs, Inc.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases. The company leverages its technology platform and differentiated human datasets to identify targets based on insights into molecular changes that drive aging. Its lead product candidate is BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor currently in Phase 1 clinical trials for the treatment of atherosclerotic cardiovascular disease, as well as for diabetic macular edema and geographic atrophy. Additionally, BioAge is developing APJ agonists for obesity, targeting both oral and parenteral administration routes. The company also has a collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets related to aging.

BioAge Labs, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BIOA. The company's shares are traded in United States Dollars (USD), which is the official currency of the United States where the company is headquartered. As a U.S.-based company listed on a major American exchange, its stock is primarily traded in USD, making it accessible to investors through standard brokerage accounts that trade on Nasdaq.

BioAge Labs, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification indicates that the company is involved in the research, development, and manufacturing of pharmaceutical products, with a focus on specialty drugs that target specific diseases or conditions. As a clinical-stage biopharmaceutical company, BioAge is primarily engaged in developing novel therapeutics for metabolic diseases and aging-related conditions, rather than mass-producing generic drugs. Its industry segment reflects its role in creating innovative treatments that address unmet medical needs.

BioAge Labs, Inc. is headquartered in Emeryville, California, United States. The company was incorporated in 2015 and has since focused on developing therapies for metabolic diseases by targeting the biological mechanisms of aging. Its location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent, research collaborations, and investment opportunities. The company's work is centered on using human datasets to identify aging-related molecular changes, which informs its pipeline of drug candidates. BioAge's collaboration with Novartis Pharma AG further underscores its commitment to advancing research in aging and disease.